Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638989 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00638989 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 30 participants.
The verdict
NCT00638989, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
Interventions
- BIOLOGICAL CAT-354 150 mg (intravenous)
- BIOLOGICAL CAT-354 150 mg (subcutaneous)
- BIOLOGICAL CAT-354 300 mg (subcutaneous)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-04-11 |
| Est. Completion | 2008-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638989
The ClinicalTrials.gov registry entry for NCT00638989 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CAT-354 150 mg (intravenous) is the first listed.
NCT00638989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00638989 about?
NCT00638989 is a clinical study titled "A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354". To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
What is the current status of trial NCT00638989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-04-11. Estimated completion is 2008-06-07.
What interventions are being tested in trial NCT00638989?
The interventions under investigation include: CAT-354 150 mg (intravenous) (BIOLOGICAL), CAT-354 150 mg (subcutaneous) (BIOLOGICAL), CAT-354 300 mg (subcutaneous) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00638989?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.